Tavalisse (fostamatinib) NDC 71332-002

NDC codes

FDA NDC Directory

Product NDC (as listed)71332-002Labeler and product segments. Claims need a package NDC.

Product NDC at billing width71332-0002Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
71332-002-01	71332000201	60 TABLET in 1 BOTTLE (71332-002-01)Marketed from May 9, 2018

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Tavalisse
Generic name (nonproprietary): fostamatinib
Active ingredients: Fostamatinib — 150 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Rigel Pharmaceuticals, Inc.
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 209299
Marketing start: May 9, 2018
Listing expires: Dec 31, 2026
Identifiers: Product ID 71332-002_78828503-b88f-4e3d-9add-8b738c4cf28eSPL ID 78828503-b88f-4e3d-9add-8b738c4cf28eSPL set ID 21149cc3-049b-43e2-b141-c9499160556cRxCUI 2044922, 2044928, 2044930, 2044932UNII SQ8A3S5101

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N471332000201 followed by a unit qualifier and the quantity

Package 71332-0002-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Nov 5, 2025.

Indications (excerpt from the label)

TAVALISSE is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. TAVALISSE is a kinase inhibitor indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under NDA 209299

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 209299
Product	Strength	Form · route	Labeler	Product NDC
Tavalissefostamatinib	Fostamatinib 100 mg/1	TabletOral	Rigel Pharmaceuticals, Inc.	71332-001